“Primary care clinicians are often the first point of contact for patients with concerns related to cognitive symptoms, yet Alzheimer’s testing has historically required a visit to a specialist,” said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. “By making this first-of-its-kind blood test available nationwide, Labcorp is giving primary care clinicians a powerful tool to help patients get answers sooner and guide next steps with confidence.”

The Elecsys pTau-181 test helps clinicians rule out Alzheimer’s disease by identifying which symptomatic patients aged 55 and older are unlikely to have amyloid pathology—abnormal protein buildup in the brain associated with Alzheimer’s disease—in the context of all clinical findings. Patients with negative results can be evaluated for other potential causes of cognitive decline, while patients with positive results can be referred for additional testing. The test was developed by Roche Diagnostics and cleared by the FDA in 2025.